Introduction
Chorioamnionitis is an important cause of preterm birth, and its frequency increases with decreasing gestational age at birth. 1, 2 Chorioamnionitis is often clinically silent; histological examination of the placenta is the gold standard for the diagnosis. Histological chorioamnionitis (HCA) is diagnosed by maternal inflammatory response with neutrophilic infiltration of placental membranes or chorionic plate, with or without a fetal inflammatory response. 3 HCA occurs more frequently in preterm than term infants and is reported in 33 to 57% of infants delivered at less than 30 weeks gestation. [4] [5] [6] [7] Intrauterine infection during chorioamnionitis activates placental and decidual cells to produce a number of proinflammatory cytokines at the fetomaternal interface, including tumor necrosis factor-a, interleukin-1b, interferon-g, interleukin-6 and interleukin-8. 8 The elevated proinflammatory cytokines are associated with an increased-incidence bronchopulmonary dysplasia 9 and brain injury, especially intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL), a strong marker for subsequent development of cerebral palsy. [10] [11] [12] A number of studies have examined the relationship between HCA and neurodevelopmental outcome. 5, 7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] A few studies reported a higher incidence of cerebral palsy, [13] [14] [15] [16] speech delay and hearing loss, 17 and lower mental developmental index 18 among infants exposed to HCA. But other studies have found no impact of HCA on the neurodevelopmental outcome in preterm infants. 5, 7, [19] [20] [21] [22] [23] A recent study reported HCA with funisitis was associated with moderate to severe disability at 2 years of age. 24 The variations in the outcome may be because of different population and study design, and lack of adjustment for potential confounding variables, such as gestational age and high rates of attrition for follow-up data (ranging from 30 to 51%). 5, 7, 21, 22 Some of the above studies were performed before the widespread use of antenatal steroids and surfactant therapy. 19, 20 We hypothesize that exposure to HCA would be associated with adverse neurodevelopmental outcome among extremely preterm infants. The objective of the present study was to examine the neurodevelopmental outcome at 30 to 42 months corrected age among preterm infants (<29 weeks) exposed to HCA, and to determine whether severity of inflammation (chorioamnionitis alone or chorioamnionitis with funisitis) has any role in the neurodevelopmental disability.
Methods

Study design and study population
This was a retrospective cohort study with prospective follow-up. All infants with gestational age <29 weeks admitted to the regional neonatal intensive-care unit in Southern Alberta, Canada, between 1 January 2000 and 31 December 2006 were eligible for the study. Infants with major congenital or chromosomal anomalies, those without placental examinations and those who did not have neurodevelopmental assessment at 30 to 42 months of corrected age were excluded from the study. The Conjoint Health Research Ethics Board of the University of Calgary approved this study and waived the need for written individual parental consent for use of anonymous electronic database.
Neonatal and neurodevelopmental outcome data were obtained from our prospective perinatal follow-up clinic database. The database contains both maternal and neonatal information collected from patient charts by trained data abstractors in accordance with a local manual of standardized operational definitions for variables and outcomes. We abstracted the following variables for this study: maternal age, maternal education, antenatal risk factors (smoking, alcohol, street drug use, pregnancy-induced hypertension), prolonged rupture of membrane (PROM >24 h), clinical chorioamnionitis (defined as the presence of maternal fever, foul-smelling amniotic fluid, maternal or fetal tachycardia), maternal antibiotic use, gestational age, birth weight, sex, antenatal steroids, mode of delivery, multiple or singleton pregnancy, Apgar scores, umbilical arterial pH, respiratory distress syndrome, culture-proven sepsis, IVH, PVL, patent ductus arteriosus, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity (ROP), duration of ventilation and hospital stay. Small for gestational age was defined as birth weight less than 10th percentile for gestational age. Bronchopulmonary dysplasia was defined as oxygen dependency at 36 weeks' postmenstrual age. 25 IVH was defined according to the criteria of Papile et al. 26 from head ultrasound performed before 14 days of postnatal age. PVL was defined as parenchymal echo densities or lucencies around the ventricles from head ultrasound performed anytime after 14 days of birth.
Placentas were examined by pediatric anatomic pathologists. After delivery, placentas were sent fresh to the pathology laboratory, examined, sampled and then placed in 10% formalin. Sections for microscopic examination were taken from each placenta as follows: (a) two from the fetal side of the placenta (b) two from the maternal side of the placenta and (c) one membrane roll, and (d) two sections from the umbilical cord, one from the proximal portion, another from the distal portion of the cord. In case of multiple gestations, in addition to routine sections, a section of the dividing membranes was also submitted. The sections were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. For this study, HCA was defined by the presence of polymorphonuclear leukocyte infiltration in the placental membranes and chorionic plate. Funisitis was diagnosed if there was polymorphonuclear cell infiltration of umbilical cord vessel walls or Wharton's jelly.
Neurodevelopmental follow-up Neurodevelopmental assessments were carried out independently by a follow-up clinic physician, certified psychologist, audiologist, physiotherapist and ophthalmologist on every child at 4, 8, 12, 18 and 36 months corrected age. The follow-up assessment consisted of medical and developmental history, as well as complete physical and neurological examination.
The primary outcome measures were cerebral palsy, cognitive delay, deafness and blindness. Cerebral palsy was diagnosed if the child had non-progressive motor impairment characterized by abnormal muscle tone in at least one extremity, and decreased range or control of movements. Cognitive delay was defined as a score >2 s.d. below the mean on standardized assessment (Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-III) or Bayley Scales of Infant Development II). Deafness was defined as sensorineural hearing loss requiring hearing aids. Blindness was defined as corrected visual acuity <20/200. Total major disability was defined as presence of one or more of the following: cerebral palsy, cognitive delay, deafness or blindness.
Data analysis
We compared the demographic parameters between infants with and without HCA. Continuous variables were analyzed using Student's t-test or Mann-Whitney U-test. Categorical variables were compared using w 2 -or Fisher's exact test. The association between HCA and the presence of neurodevelopmental outcomes (cerebral palsy, cognitive delay, deafness, blindness and total major disabilities) was examined using generalized estimating equations with a binomial distribution and a logit link to account for correlations in multiple births. Because of the sample size, an exchangeable correlation matrix was assumed. And because of small event numbers, all associations were checked sequentially with gestational age, maternal hypertension, PROM>24 and a multiple birth indicator for cognitive delays, deafness and blindness. For cerebral palsy and major disabilities, which had a greater number of outcomes, the association was checked using no more than three other potential confounders at a time. Odds ratio (OR) and 95% confidence interval (CI) were computed for the outcomes. In addition, we compared the neurodevelopmental outcome of infants with chorioamnionitis alone, and those with chorioamnionitis with funisitis. All P-values were based on twosided test results and P-value of <0.05 was considered statistically significant. Data analyses were performed using SAS 9.2 and was used for all analyses. (SAS Institute, Cary, NC, USA)
Results
During the study period, a total of 628 infants with gestational age of <29 weeks were admitted to the neonatal intensive-care unit. Figure 1 presents the flow diagram of the study population. Ninetynine infants were excluded because of lack of placental histology report (93 infants), multiple congenital anomalies (4 infants) or syndrome (2 infants). There was no significant difference in the demographic parameters between excluded and included infants in the study, except for birth weight. Of the 529 eligible infants, 270 (51%) had HCA. A total of 46 of the 270 (17%) infants with HCA died, as compared with 41 of the 259 (16%) infants dead without HCA (P>0.05).
Of the 442 surviving infants, 384 (87%) subjects who had neurodevelopmental assessment formed the study cohort for analysis. Of the 384 infants, 197 (51%) infants were born to mother with HCA. Of the 197 infants with HCA, 140 (71%) had evidence of fetal inflammatory response (funisitis) and the remaining 57 (29%) had evidence of only maternal inflammatory response in the placenta. The proportion of infants who were lost to follow-up was not different between the two groups. There was no difference in the clinical characteristics between infants who completed neurodevelopmental evaluation and infants who were lost to follow-up.
The maternal and birth characteristics of the HCA and no HCA groups are presented in Table 1 . Mothers with HCA were more likely to have clinical chorioamnionitis, PROM and received antibiotics. There was no difference in the socioeconomic status between the two groups. Infants with HCA were significantly of lower gestational age, more likely to be singleton, appropriate for gestational age and had lower 5-min Apgar score, as compared with the group of infants without HCA.
The common neonatal morbidities between the two groups are presented in Table 2 . Infants with HCA were more likely to have a higher incidence of IVH (all grades), IVH grade X3, PVL and ROP Xstage 3.
Neurodevelopmental outcomes
The mean age at neurodevelopmental follow-up was similar between the two groups (37.2±2.1 months in the HCA group vs 37.2±2.1 months in the group without HCA). Compared with infants without HCA, infants with HCA had increased rates of cerebral palsy (12.6% vs 6.4%, P ¼ 0.04). There were no significant differences in the rates of cognitive delay (7.6% vs 7.4%), deafness (4% vs 2.6%), blindness (2.5% vs 2.6%) and total major disabilities (17.2% vs 13.3%) between the two groups. Of the 25 out of 197 (12.6%) children who developed cerebral palsy in the HCA group, 17 had moderate to severe cerebral palsy and 8 had mild spastic diplegia. Of the 12 out of 187 (6.4%) children with cerebral palsy in the group without HCA, 10 had moderate to severe cerebral palsy and 2 had mild cerebral palsy. The rate of moderate and severe cerebral palsy was not significantly different between the two groups (8.6% vs 5.3%, P ¼ 0.20). Of the 384 infants, 332 (86%) had cognitive testing. In 10 children, the cognitive testing could not be performed because of severe neurological or neurodevelopmental impairment. The mean cognitive score was 96 ± 15 in the HCA group as compared with 97 ± 16 in the group without HCA (P ¼ 0.40). There was no difference in the proportion of infants with cognitive delay (score <70) between the two groups. Table 3 shows the association between HCA and neurodevelopmental outcomes. After adjusting for perinatal factors, HCA was found to be associated with cerebral palsy (adjusted OR: 2.45, 95% CI 1.11 to 5.40). The factors adjusted for cerebral palsy included gestational age, maternal hypertension, PROM>24, as the multiple birth indicator did not alter the reported ORs. However, HCA was not associated with cognitive delay, deafness, blindness or total major disabilities. Table 4 describes the neurodevelopmental outcome based on severity of inflammation. There was a trend towards increased risk of cerebral palsy with increasing severity of chorioamnionitis (i.e., infants with HCA with funisitis). The other neurodevelopmental outcomes were similar among the three groups.
Discussion
The incidence of HCA in this cohort (51%) is similar to that reported previously. 6, 7 Our study shows that HCA is associated with severe IVH (grade 3 and 4), PVL and ROP (stage X3). This association became no longer significant after adjusting for gestational age. Previous studies have also reported increased IVH and PVL among infants born to women with HCA. [11] [12] [13] Previous studies showed higher rates of ROP in infants born to mothers with HCA compared with those born to mothers without signs of inflammation. 5, 27 In contrast, Woo et al. 28 reported that the clinical chorioamnionitis and elevated maternal white blood cell count, but not HCA, were significantly associated with ROP. Maternal systemic inflammation might contribute to the development of ROP in preterm infants by decreasing levels of insulin-like growth factor-1. 28 Low levels of insulin-like growth factor-1 have been associated with an increased risk of ROP, and the insulin-like growth factor-1 levels vary inversely with the severity of ROP.
We observed that HCA is associated with 2.5-fold increased odds of developing cerebral palsy in preterm infants. There is also a trend towards increased risk of cerebral palsy with increasing fetal inflammatory process (i.e., funisitis). Our finding of increased cerebral palsy with HCA is in agreement with others. [13] [14] [15] In term infants, there appears to be a four-fold increased risk of cerebral palsy from chorioamnionitis. 13 In a population-based case-control study from Sweden, Jacobsson et al. 15 reported that HCA was associated with increased risk of cerebral palsy in preterm infants (OR 3.6; 95% CI 1.16 to 12.1). Similarly, clinical chorioamnionitis was associated with increased risk of cerebral palsy in preterm infants (OR 2.3; 95% CI 1.3 to 4.2). 16 In contrast to our finding, Grether et al. 23 reported that neither clinical chorioamnionitis nor HCA was associated with cerebral palsy in children born before 32 weeks. A meta-analysis of observational studies reported before 2000 showed that HCA was associated with cystic PVL (relative risk 2.1 95% CI 1.5 to 2.3), but not with cerebral palsy (relative risk 1.6; 95% CI 0.9 to 2.7) in preterm infants. 13 All the five studies included in that metaanalysis were performed before routine administration of antenatal steroid and before beginning routine surfactant therapy. Moreover, the definition of the outcome variable (cerebral palsy) differed among studies. A recent meta-analysis of studies published after 2000 showed that both clinical chorioamnionitis and HCA are associated with cerebral palsy. However, this meta-analysis did not examine term and preterm infants separately. 14 Similar to previous studies, 7,20 -22 we did not find an association between HCA and other neurodevelopmental disabilities, such as cognitive delay, deafness and blindness. In contrast to our findings, Hendson et al. 18 reported a four-point reduction in mental developmental index in infants with HCA. Andrews et al. 22 reported that the gestational age at birth, rather than chorioamnionitis, is independently associated with adverse neurodevelopmental outcome. For each 1 week gained between 23 and 32 weeks, there was a 25% lower odd of an IQ <70 and major morbidity at 6 years of age per gestational week. 22 Suppiej et al. 17 reported an increased risk of speech delay and hearing loss at 18 months in infants born prematurely with HCA. The authors suggested that HCA and its inflammatory cascade could interfere with the delicate developmental phase of the cochlea. The authors used a parental questionnaire to assess the outcome and did not adjust for potential confounding variables, including gestational age, use of medication and Apgar score.
Severe chorioamnionitis is associated with increased levels of cytokines. The presence of proinflammatory cytokines in the central nervous system has been shown to inhibit proliferation of neuronal precursor cells, activate astrogliosis and stimulate oligodendrocyte cell death, all of which increase the risk of white-matter injury. 29 White-matter injury and IVH are associated with development of cerebral palsy and neurodevelopmental disability. However, the effect of HCA with funisitis on the neurodevelopmental outcome is not clearly understood. Yoon et al. 30 reported that antenatal exposure to intra-amniotic inflammation and evidence of a systemic fetal inflammatory response (funisitis) are strong and independent risk factors for the subsequent development of cerebral palsy at the age of 3 years.
We observed an increase in the incidence of cerebral palsy in infants who had HCA with fetal inflammatory response (funisitis). Rovira et al. 24 observed that funisitis is associated significantly with moderate to severe disability at 2 years of age. An adverse cognitive ability at 8 years of age was observed only in children with a history of low gestational age and more severe degrees of HCA. 31 The hypothesized mechanisms of how chorioamnionitis leads to cerebral palsy include (a) elevated levels of fetal cytokines causing direct injury to fetal brain, that is, fetal inflammatory response; 11, 30 (b) interruption of placental gas exchange and blood flow, resulting in hypoxic ischemic brain injury in the fetus; 32 (c) maternal fever raising the core temperature of the fetus, which in turn may be harmful to the developing brain, especially in the setting of cerebral ischemia; 33 and (d) direct infection of fetal brain or meninges, although this is rarely seen. 23 The strength of this study includes comprehensive multidisciplinary follow-up with an 87% follow-up rate. All neurological and neurodevelopmental assessments were performed by individuals who were unaware of the infant's placental histology reports. Use of clear operational definitions provided a basis for accurate measurement of all variables. We also use robust statistical analysis to adjust for multiple gestations, using generalized estimating equation. Although the neonatal data was collected by an individual using standardized definitions and protocols, placental histology was read by two pathologists during the study period. The inter-observer and intra-observer reliability of the placental reports was not examined. Multicenter prospective cohort studies with appropriate sample size are recommended for such studies. Standardized definition and grading of the severity of HCA are highly recommended for future studies.
There is limited information on how to diagnose silent chorioamnionitis during pregnancy. In general, most clinician relies on clinical diagnosis of chorioamnionitis for planning delivery and antenatal counseling, especially in cases of PROM. In the present study, only one third of the cases of HCA had any signs of clinical chorioamnionitis. This is similar to previous studies. 24 As HCA is associated with severe brain injury and cerebral palsy, it may be important for the physicians to counsel the parents after getting the placental pathology report. Infants exposed to HCA should have regular neurodevelopmental follow-up.
Conclusion
In conclusion, HCA is associated with an increased risk of cerebral palsy in preterm infants <29 weeks. We would like to emphasize the need for counseling the parents about increased risk of severe brain injury and later cerebral palsy, especially after the diagnosis of HCA. Future studies should examine the effect of HCA with funisitis (severe chorioamnionitis) on the neonatal and neurodevelopmental outcome in this vulnerable age group.
